Results 51 to 60 of about 8,704 (178)

Long‐term follow‐up of chronic central serous chorioretinopathy patients receiving oral eplerenone and half‐dose photodynamic therapy in the SPECTRA trial: SPECTRA trial report No. 4

Acta Ophthalmologica, Volume 104, Issue 5, Page e565-e577, August 2026.
Abstract Purpose Assessing the 24‐month treatment outcome of half‐dose photodynamic therapy (PDT) or oral eplerenone in chronic central serous chorioretinopathy (cCSC). Methods Multicentre randomized clinical trial included cCSC patients from the SPECTRA trial who were randomized to receive half‐dose PDT or oral eplerenone.
Helena M. A. Feenstra, Issam El Mansori, Thomas J. van Rijssen, Roula Tsonaka, Roselie M. H. Diederen, Carel B. Hoyng, Reinier O. Schlingemann, Camiel J. F. Boon, Elon H. C. van Dijk   +8 more
wiley   +1 more source

The Effects of Combined Antihypertensive and Antidiabetic Therapies on Cardiovascular Outcomes: A Systematic Review and Meta‐Analysis

Diabetes, Obesity and Metabolism, Volume 28, Issue 8, Page 6874-6887, August 2026.
ABSTRACT Aims Hypertension and diabetes frequently coexist, yet the net clinical impact of intentionally combining antihypertensive (AHTN) and antidiabetic (ADA) therapies on cardiovascular (CV) outcomes is uncertain. Here we quantified the effects of AHTN and ADA co‐therapy on CV and blood pressure (BP)/heart rate (HR) outcomes.
Wan Chin Hsieh, Brandon Michael Henry, István Édes   +2 more
wiley   +1 more source

Eplerenone inhibits aldosterone-induced CRP generation in rat vascular smooth muscle cells by regulating the MR-ROS-ERK1/2 signal pathway

European Journal of Inflammation, 2017
Atherosclerosis is a chronic inflammatory disease in the vessel wall. As a representative inflammatory cytokine, C-reactive protein (CRP) participates in the formation and development of atherosclerosis.
Xiaolu Zhang, Juntian Liu, Xiaoming Pang, Jingjing Zhao, Shouzhu Xu, Jing Zhao   +5 more
doaj   +1 more source

Preventive Effect of Mineralocorticoid Receptor Antagonists Against Proteinuria Induced by Atezolizumab Plus Bevacizumab Therapy in Hepatocellular Carcinoma: A Multicenter Retrospective Study

Hepatology Research, Volume 56, Issue 8, Page 1225-1234, August 2026.
Mineralocorticoid receptor antagonists are known to reduce proteinuria in chronic kidney disease, but their effectiveness in preventing bevacizumab‐related proteinuria has not been well established. In the present multi‐institutional retrospective study, we found that these agents significantly delay the onset of moderate or higher grade proteinuria ...
Tomoki Hori, Kazuhiro Yamamoto, Hiroshi Aoi, Yusuke Koizumi, Makoto Kuromatsu, Aiko Fukui, Hiroyo Okamoto, Atsushi Hirata, Kentaro Shinmori, Yuki Imanaka, Miyu Namba, Keisuke Nakanishi, Syunsuke Kitamura, Hideo Tsushima, Ikuko Yano, Kei Moriya, Masaru Matsui, Shigeki Ikushima   +17 more
wiley   +1 more source

Modulation of the acute defence reaction by eplerenone prevents cardiac disease progression in viral myocarditis

ESC Heart Failure, 2020
Aims Left ventricular (LV) dysfunction in viral myocarditis is attributed to myocardial inflammation and fibrosis, inducing acute and long‐time cardiac damage. Interventions are not established.
Carsten Tschöpe, Sophie Van Linthout, Sebastian Jäger, Robert Arndt, Tobias Trippel, Irene Müller, Ahmed Elsanhoury, Susanne Rutschow, Stefan D. Anker, Heinz‐Peter Schultheiss, Matthias Pauschinger, Frank Spillmann, Kathleen Pappritz   +12 more
doaj   +1 more source

Natural History of Chronic Kidney Disease in Sickle Cell Disease

American Journal of Hematology, Volume 101, Issue 7, Page 1456-1477, July 2026.
ABSTRACT Kidney complications, referred to as nephropathy, develop early in sickle cell disease (SCD). In addition to its known morbidity, abundant data show that chronic kidney disease (CKD) is associated with an increased mortality risk in SCD. Increasing evidence suggests that the natural history of SCD nephropathy is progressive. Initial glomerular
Kenneth I. Ataga
wiley   +1 more source

Evaluation of the Antioxidant Status of Ethanolic Extract of Hypericum perforatum and Its Effect on Performance, Immune System, Antioxidant Status and Plasma Biochemical Indices of Broiler Chickens

Veterinary Medicine and Science, Volume 12, Issue 4, July 2026.
Hypericum perforatum ethanolic extract (HPEE) at the levels of 0, 150, 300 and 450 mg/kg were used and dietary treatments did not affect growth performance including feed intake, body weight and feed conversion ratio. The HPPE reduced the abdominal fat and improved meat quality in broilers.
Hojjat Seraji‐Kopkan, Seyyed Javad Hosseini‐Vashan, Nazar Afzali, Mohammad Hassan Namaei   +3 more
wiley   +1 more source

Eplerenone for Central Serous Chorioretinopathy: Is There Still Room for This Treatment?

Biomedicines
Background/Objectives: The purpose of this study was to evaluate the efficacy and safety of oral eplerenone in patients with acute and chronic central serous chorioretinopathy (CSCR).
Irini Chatziralli, Chrysa Agapitou, Stamatios Lampsas, Alexandros Chatzirallis, Alexia Risi-Koziona, Rafaela Smarlamaki, Konstantinos Pappelis, George Theodossiadis, Panagiotis Theodossiadis   +8 more
doaj   +1 more source

Outcomes With Finerenone by Baseline Treatment Goals in Type 2 Diabetes and Chronic Kidney Disease: A FIDELITY Analysis

Diabetes, Obesity and Metabolism, Volume 28, Issue 7, Page 6022-6033, July 2026.
ABSTRACT Aims The American Diabetes Association recommends achieving treatment goals (glycated haemoglobin ≤ 53 mmol/mol [7.0%], blood pressure < 130/80 mmHg, low‐density lipoprotein cholesterol < 1.81 mmol/L and use of sodium–glucose cotransporter‐2 inhibitors or glucagon‐like peptide‐1 receptor agonists), to reduce cardiovascular and kidney ...
João Sérgio Neves, Ana Rita Leite, Francisco Vasques‐Nóvoa, Bertram Pitt, Gerasimos Filippatos, Luis M. Ruilope, Peter Rossing, Stefan D. Anker, Gianluigi Savarese, Charlie A. B. Scott, Andrea Lage, Meike D. Brinker, João Pedro Ferreira   +12 more
wiley   +1 more source

Prescription patterns of SGLT2 inhibitors in patients admitted to a tertiary health service with heart failure with reduced ejection fraction: an opportunity to improve

Internal Medicine Journal, Volume 56, Issue 7, Page 1149-1156, July 2026.
Abstract Background Sodium‐glucose co‐transporter 2 inhibitors (SGLT2is) improve symptoms, reduce hospitalisations and increase survival in patients with heart failure with reduced ejection fraction (HFrEF). This study evaluated SGLT2i prescribing compliance in hospitalised patients with HFrEF at an Australian tertiary hospital.
Salim Memon, Kanishaa Subhaharan, Tasnuba Ashan, Rogges Anandarajah, Nuwan Jasenthu Kankanamage   +4 more
wiley   +1 more source